24 Nov 2020 The analyst gave a rating of “Overweight” to PFE with a target price of $53 per share, which at press time represented a projected 12-month return

2020-06-06

PDF 2,975KB. Leading in sustainability - webcast replay. AstraZeneca currently has 2 sell ratings, 1 hold rating and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AZN will outperform the market and that investors should add to their positions of AstraZeneca.

Astrazeneca analyst ratings

Broker forecasts. Due to changes in how we source investment data, Broker Forecasts are not available. We're In depth view into AZN (AstraZeneca) stock including the latest price, news, dividend history, earnings information and financials. AstraZeneca PLC stock rating and analysis - : a summary of key financial strength and profitability metrics. 20 Jul 2020 Moderna, which is among biotech's hottest stocks, was also down as much as 18 % as JPMorgan downgraded its rating to the equivalent of a hold 24 Nov 2020 The analyst gave a rating of “Overweight” to PFE with a target price of $53 per share, which at press time represented a projected 12-month return Should you invest in AstraZeneca (LSE:AZN)?

AZN's average price target has moved up $6.85 over the prior 143 days. AZN reports an average of 7.17% for its upside Analysis and Opinions about AZN-N Allan Tong's Discover Picks The AZN stock currently trades at a 64x PE and pays a not-bad 2.69% dividend yield.

2021-02-11 · AstraZeneca PLC (AZN.L) (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Shore Capital in a research report issued to clients and investors on Thursday, Digital Look reports. A number of other equities research analysts have also weighed in on AZN. Morgan Stanley set a GBX 9,900 ($129.34) price objective on shares of […]

The average twelve-month target price […] Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of $60.00. Syndax Pharmaceuticals (SNDX) Morgan Stanley analyst David Lebovitz maintained a Hold rating on Syndax Pharmaceuticals today and set a price target of $16.00. The company’s shares closed last Friday at $15.03. 2021-02-11 · AstraZeneca PLC (AZN.L) (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Shore Capital in a research report issued to clients and investors on Thursday, Digital Look reports.

2021-04-13 · Based on estimates by 25 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the AstraZeneca PLC (AZN) stock as a Hold, while 21 rate it as a Buy. 2 analyst(s) rate it as outperform while none of them rated it as underperform, whereas 1 suggest the stock as a Sell.

Syndax Pharmaceuticals (SNDX) Morgan Stanley analyst David Lebovitz maintained a Hold rating on Syndax Pharmaceuticals today and set a price target of $16.00. The company’s shares closed last Friday at $15.03. 2021-02-11 · AstraZeneca PLC (AZN.L) (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Shore Capital in a research report issued to clients and investors on Thursday, Digital Look reports. A number of other equities research analysts have also weighed in on AZN. Morgan Stanley set a GBX 9,900 ($129.34) price objective on shares of […] AstraZeneca Plc fell from a record high in New York trading after data for the company’s Covid-19 vaccine candidate, though promising, fueled concerns about whether it can match competitors. See today’s analyst top recommended stocks >> AstraZeneca (AZN) Leerink Partners analyst Andrew Berens maintained a Buy rating on AstraZeneca today and set a price target of $63.00. The company’s shares closed last Tuesday at $47.99.

$48.44 0.02 0.04%. AFTER 2020-08-14 · No. of Analysts: 3: 3: 5: 5: Avg. Estimate: 7.14B: 7.33B: 31.47B: 37.55B: Low Estimate: 6.86B: 6.95B: 29.94B: 33.62B: High Estimate: 7.59B: 7.84B: 33.31B: 40.56B: Year Ago Sales: 6.35B: 6.28B: 26 No. of analysts: 2: 2: 4: 4: Avg. Estimate: 7.22B: 7.52B: 32.02B: 38.08B: Low estimate: 6.86B: 7.2B: 30.26B: 34.49B: High estimate: 7.59B: 7.85B: 33.31B: 40.56B: Year ago sales: 6.35B: 6.28B: 26.62B: 32.02B: Sales growth (year/est) 13.70%: 19.90%: 20.30%: 18.90% 20 Wall Street analysts have issued ratings and price targets for AstraZeneca in the last 12 months. Their average twelve-month price target is GBX 8,759.44 The high price target for AZN is £102 and the low price target for AZN is GBX 6,690. There are currently 5 sell ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy. 15 Wall Street analysts have issued ratings and price targets for AstraZeneca in the last 12 months. Their average twelve-month price target is $89.50, predicting that the stock has a possible upside of 79.75%. The high price target for AZN is $175.00 and the low price target for AZN is $60.00.
What is instegsjobb

AZN has been the topic of several other research reports.
Office 98 mac

20 Jul 2020 Moderna, which is among biotech's hottest stocks, was also down as much as 18 % as JPMorgan downgraded its rating to the equivalent of a hold

Cruise firm But Morningstar analyst Allen Good argues that BP and Shell can ride out the current crisis without cuts.

See Astrazeneca PLC (AZN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Senior Ratings Analyst, Deutsche Bank. Civilekonom Business Analyst, Evalueserve. Civilekonom plastikkirurgi och käkkirurgi AstraZeneca –GÄRTUNA, Celgene AB (a Bristol BilMånsson British Cars - Land Rover; TerraNet - Analyst Group. Value Cars Sweden AB, 559138-4929- På hittar du kostnadsfri rating på alla Novartis has Lucentis under review in the EU for approval of the and worked four years as equity research analyst at Remium Nordic.

2020-07-13 · AstraZeneca plc (NYSE:AZN) has been assigned a consensus rating of “Hold” from the thirteen ratings firms that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price […] Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of $60.00. Syndax Pharmaceuticals (SNDX) Morgan Stanley analyst David Lebovitz maintained a Hold rating on Syndax Pharmaceuticals today and set a price target of $16.00. The company’s shares closed last Friday at $15.03.